Nasal and Plasma Severe Acute Respiratory Syndrome Coronavirus 2 RNA Levels Are Associated With Timing of Symptom Resolution in the ACTIV-2 Trial of Nonhospitalized Adults With Coronavirus Disease 2019

Yijia Li; Linda J Harrison; Kara W Chew; Judy S Currier; David A Wohl; Eric S Daar; Teresa H Evering; Ryan Wu; Mark Giganti; Justin Ritz; Arzhang Cyrus Javan; Robert W Coombs; Carlee Moser; Michael D Hughes; Joseph J Eron; Davey M Smith; Jonathan Z Li

doi:10.1093/cid/ciac818

Nasal and Plasma Severe Acute Respiratory Syndrome Coronavirus 2 RNA Levels Are Associated With Timing of Symptom Resolution in the ACTIV-2 Trial of Nonhospitalized Adults With Coronavirus Disease 2019

Clin Infect Dis. 2023 Feb 18;76(4):734-737. doi: 10.1093/cid/ciac818.

Authors

Yijia Li¹, Linda J Harrison², Kara W Chew³, Judy S Currier³, David A Wohl⁴, Eric S Daar⁵, Teresa H Evering⁶, Ryan Wu², Mark Giganti², Justin Ritz², Arzhang Cyrus Javan⁷, Robert W Coombs⁸, Carlee Moser², Michael D Hughes², Joseph J Eron⁴, Davey M Smith⁹, Jonathan Z Li¹

Affiliations

¹ Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
² Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.
³ Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA, USA.
⁴ Department of Medicine, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA.
⁵ Lundquist Institute at Harbor-UCLA Medical Center, Los Angeles, California, USA.
⁶ Department of Medicine, Weill Cornell Medicine, New York, New York, USA.
⁷ National Institutes of Health, Bethesda, Maryland, USA.
⁸ Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
⁹ Department of Medicine, University of California, San Diego, La Jolla, California, USA.

Abstract

Acute Coronavirus Disease 2019 symptoms limit daily activities, but little is known about its association with severe acute respiratory syndrome coronavirus 2 viral burden. In this exploratory analysis of placebo recipients in the ACTIV-2/A5401 platform trial, we showed that high anterior nasal RNA levels and detectable plasma RNA were associated with delayed symptom improvement. Clinical Trials Registration. https://clinicaltrials.gov/ct2/show/NCT04518410.

Keywords: COVID-19; RNA; SARS-CoV-2; symptom duration.

Publication types

Randomized Controlled Trial
Research Support, N.I.H., Extramural

MeSH terms

Adult
COVID-19*
Humans
RNA
SARS-CoV-2
Viral Load

Nasal and Plasma Severe Acute Respiratory Syndrome Coronavirus 2 RNA Levels Are Associated With Timing of Symptom Resolution in the ACTIV-2 Trial of Nonhospitalized Adults With Coronavirus Disease 2019

Authors

Affiliations

Abstract

Publication types

MeSH terms

Substances

Associated data

Grants and funding